Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 82 articles: HTML format

Single Articles

March 2023
1. WIESE D, Islami F, Henry KA
   Changes in geographic accessibility to mammography by state and rural-urban status, United States, 2006-2022.
   J Natl Cancer Inst. 2023;115:337-340.
   PubMed     Abstract available
   
   
   
2. 
   Correction to: RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
   J Natl Cancer Inst. 2023 Mar 6:djad041. doi: 10.1093.
   PubMed    
   
   
   February 2023
3. LOVETT SM, Sandler DP, O'Brien KM
   Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study.
   J Natl Cancer Inst. 2023 Feb 20:djad038. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. 
   Correction to: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
   J Natl Cancer Inst. 2023 Feb 16:djad023. doi: 10.1093.
   PubMed    
   
   
   
5. CHAVEZ-MACGREGOR M, Lei X, Malinowski C, Zhao H, et al
   Medicaid expansion, chemotherapy delays, and racial disparities among women with early-stage breast cancer.
   J Natl Cancer Inst. 2023 Feb 16:djad033. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. BIKOMEYE JC, Zhou Y, McGinley EL, Canales B, et al
   Historical Redlining and Breast Cancer Treatment and Survival among older Women in the US.
   J Natl Cancer Inst. 2023 Feb 16:djad034. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. MALTONI R, Puccetti M, Poli F, Martinelli G, et al
   Re: Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
   J Natl Cancer Inst. 2023 Feb 10:djad021. doi: 10.1093.
   PubMed    
   
   
   
8. JI J, Sun CL, Cohen HJ, Muss HB, et al
   Toxicity Risk Score and Clinical Decline After Adjuvant Chemotherapy in Older Breast Cancer Survivors.
   J Natl Cancer Inst. 2023 Feb 10:djad029. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. EVANS DG, Woodward ER
   RE: Heterozygous BRCA1/BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
   J Natl Cancer Inst. 2023;115:224-225.
   PubMed    
   
   
   January 2023
10. JONES RR, Fisher JA, Medgyesi DN, Buller ID, et al
    Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a U.S. cohort.
    J Natl Cancer Inst. 2023 Jan 12:djad004. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. JENSEN BW, Aarestrup J, Blond K, Jorgensen ME, et al
    Childhood body mass index trajectories, adult-onset type 2 diabetes, and obesity-related cancers.
    J Natl Cancer Inst. 2023;115:43-51.
    PubMed     Abstract available
    
    
    December 2022
12. LEONE JP, Freedman RA, Leone J, Tolaney SM, et al
    Survival in male breast cancer over the past three decades.
    J Natl Cancer Inst. 2022 Dec 30:djac241. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. BRASO-MARISTANY F, Griguolo G, Chic N, Pascual T, et al
    HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
    J Natl Cancer Inst. 2022 Dec 28:djac227. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. BADVE SS, Gokmen-Polar Y
    A predictor of response in HER2+ breast cancer-at last!
    J Natl Cancer Inst. 2022 Dec 28:djac228. doi: 10.1093.
    PubMed    
    
    
    
15. LANGE M, Arbogast SL, Hardy-Leger I, Rigal O, et al
    Cognitive change in breast cancer patients up to 2 years after diagnosis.
    J Natl Cancer Inst. 2022 Dec 26:djac240. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. DENG Z, Jones MR, Wang MC, Wolff AC, et al
    Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy.
    J Natl Cancer Inst. 2022 Dec 19:djac220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. CHANG CJ, O'Brien KM, Keil AP, Gaston SA, et al
    Use of Straighteners and Other Hair Products and Incident Uterine Cancer.
    J Natl Cancer Inst. 2022;114:1636-1645.
    PubMed     Abstract available
    
    
    
18. CHAPMAN CH, Jagsi R, Griffith KA, Moran JM, et al
    Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients.
    J Natl Cancer Inst. 2022;114:1646-1655.
    PubMed     Abstract available
    
    
    November 2022
19. CHLEBOWSKI RT, Aragaki AK, Pan K
    RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
    J Natl Cancer Inst. 2022 Nov 21:djac213. doi: 10.1093.
    PubMed    
    
    
    
20. PEDERSON HJ, Faubion SS, Pruthi S, Goldfarb S, et al
    RE: Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study.
    J Natl Cancer Inst. 2022 Nov 21:djac211. doi: 10.1093.
    PubMed    
    
    
    
21. DJERROUDI L, Cabel L, Bidard FC, Vincent-Salomon A, et al
    Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy?
    J Natl Cancer Inst. 2022;114:1434-1436.
    PubMed    
    
    
    
22. KRATZ CP, Smirnov D, Autry R, Jager N, et al
    Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.
    J Natl Cancer Inst. 2022;114:1523-1532.
    PubMed     Abstract available
    
    
    
23. KRAUT R
    RE: Informing Women about Overdetection in Breast Cancer Screening: Two-Year Outcomes from a Randomized Trial.
    J Natl Cancer Inst. 2022 Nov 4. pii: 6798630. doi: 10.1093.
    PubMed    
    
    
    October 2022
24. LIM BWX, Li N, Mahale S, Mcinerny S, et al
    Somatic Inactivation of Breast Cancer Predisposition Genes in Tumours Associated with Pathogenic Germline Variants.
    J Natl Cancer Inst. 2022 Oct 31. pii: 6782963. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. OESTERREICH S, Nasrazadani A, Zou J, Carleton N, et al
    Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
    J Natl Cancer Inst. 2022 Oct 14. pii: 6758318. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. LEE CI, Elmore JG
    Cancer Risk Prediction Paradigm Shift: Using Artificial Intelligence to Improve Performance and Health Equity.
    J Natl Cancer Inst. 2022;114:1317-1319.
    PubMed    
    
    
    
27. CATHCART-RAKE EJ, Ruddy KJ
    Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?
    J Natl Cancer Inst. 2022;114:1315-1316.
    PubMed    
    
    
    
28. SUNG H, Koka H, Marino N, Pfeiffer RM, et al
    Association of Genetic Ancestry With Terminal Duct Lobular Unit Involution Among Healthy Women.
    J Natl Cancer Inst. 2022;114:1420-1424.
    PubMed     Abstract available
    
    
    September 2022
29. COGAN JC, Raghunathan RR, Beauchemin MP, Accordino MK, et al
    New and Persistent Sedative-Hypnotic Use after Adjuvant Chemotherapy for Breast Cancer.
    J Natl Cancer Inst. 2022 Sep 20. pii: 6706799. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. BOWER JE, Partridge AH, Wolff AC, Cole SW, et al
    Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes.
    J Natl Cancer Inst. 2022 Sep 20. pii: 6706813. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. RICHMAN I, Tessier-Sherman B, Galusha D, Oladele CR, et al
    Breast Cancer Screening During the COVID-19 Pandemic: Moving from Disparities to Health Equity.
    J Natl Cancer Inst. 2022 Sep 7. pii: 6693627. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2022
32. LAMBERTINI M, Fielding S, Loibl S, Janni W, et al
    Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.
    J Natl Cancer Inst. 2022;114:1117-1126.
    PubMed     Abstract available
    
    
    
33. PUNGLIA RS, Hassett MJ
    Variation in Cardiac Dose Explains a "Fraction" of the Disparities among Breast Cancer Patients.
    J Natl Cancer Inst. 2022 Aug 2. pii: 6653305. doi: 10.1093.
    PubMed    
    
    
    
34. SCHUMACHER JR, Neuman HB, Yu M, Vanness DJ, et al
    Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01).
    J Natl Cancer Inst. 2022 Aug 1. pii: 6652887. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2022
35. LEHMAN CD, Mercaldo S, Lamb LR, King TA, et al
    Deep Learning vs Traditional Breast Cancer Risk Models to Support Risk-Based Mammography Screening.
    J Natl Cancer Inst. 2022 Jul 25. pii: 6649701. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. COLD S, Cold F, Jensen MB, Cronin-Fenton D, et al
    Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
    J Natl Cancer Inst. 2022 Jul 20. pii: 6645744. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. LIGORIO F, Di Cosimo S, Verderio P, Ciniselli CM, et al
    Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab.
    J Natl Cancer Inst. 2022 Jul 5. pii: 6631230. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
38. ROBERTI S, van Leeuwen FE, Ronckers CM, Krul IM, et al
    Radiotherapy-related dose and irradiated volume effects on breast cancer risk among Hodgkin lymphoma survivors.
    J Natl Cancer Inst. 2022 Jun 30. pii: 6623416. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. JUNG AY, Ahearn TU, Behrens S, Middha P, et al
    Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies.
    J Natl Cancer Inst. 2022 Jun 20. pii: 6611725. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. SCHEDIN P, Palmer JR
    Can breast cancer prevention strategies be tailored to biologic subtype and unique reproductive windows?
    J Natl Cancer Inst. 2022 Jun 20. pii: 6611724. doi: 10.1093.
    PubMed    
    
    
    
41. MOSS JL, Pinto CN, Srinivasan S, Cronin KA, et al
    Enduring Cancer Disparities by Persistent Poverty, Rurality, and Race: 1990-1992 to 2014-2018.
    J Natl Cancer Inst. 2022;114:829-836.
    PubMed     Abstract available
    
    
    
42. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed     Abstract available
    
    
    April 2022
43. SCHRIJVER LH, Mooij TM, Pijpe A, Sonke GS, et al
    Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    J Natl Cancer Inst. 2022;114:540-552.
    PubMed     Abstract available
    
    
    
44. KRIEGER N
    RE: Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region.
    J Natl Cancer Inst. 2022 Apr 4. pii: 6563193. doi: 10.1093.
    PubMed    
    
    
    
45. LOHMANN AE, Ennis M, Parulekar WR, Chen BE, et al
    The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer.
    J Natl Cancer Inst. 2022 Apr 4. pii: 6563195. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2022
46. QIN X, Huckfeldt P, Abraham J, Yee D, et al
    Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence among Older Women with Breast Cancer.
    J Natl Cancer Inst. 2022 Mar 25. pii: 6554201. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. FANG Z, Song M, Lee DH, Giovannucci EL, et al
    The Role of Mendelian Randomization Studies in Deciphering the Effect of Obesity on Cancer.
    J Natl Cancer Inst. 2022;114:361-371.
    PubMed     Abstract available
    
    
    February 2022
48. DE NONNEVILLE A, Finetti P, Mamessier E, Bertucci F, et al
    RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
    J Natl Cancer Inst. 2022 Feb 11. pii: 6527095. doi: 10.1093.
    PubMed    
    
    
    
49. BELCHER EK, Culakova E, Gilmore NJ, Hardy SJ, et al
    Inflammation, Attention, and Processing Speed in Patients with Breast Cancer before and after Chemotherapy.
    J Natl Cancer Inst. 2022 Feb 4. pii: 6522123. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
50. MOSKOWITZ CS
    Towards Using Breast Cancer Risk Prediction Models for Guiding Screening Decisions.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506526. doi: 10.1093.
    PubMed    
    
    
    
51. KERLIKOWSKE K, Chen S, Golmakani MK, Sprague BL, et al
    Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506541. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. DACKUS GMHE, Jozwiak K, Hauptmann M, Linn SC, et al
    Response to Klar and Adams.
    J Natl Cancer Inst. 2022;114:167-168.
    PubMed    
    
    
    December 2021
53. SCHLEE VILLODRE E, Hu X, Eckhardt BL, Larson R, et al
    NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459176. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
54. ISLAMI F, Ward EM, Sung H, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
    J Natl Cancer Inst. 2021;113:1648-1669.
    PubMed     Abstract available
    
    
    
55. RUGO HS, Loi S, Adams S, Schmid P, et al
    PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2021;113:1733-1743.
    PubMed     Abstract available
    
    
    
56. GAVRIELATOU N, Shafi S, Gaule P, Rimm DL, et al
    PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.
    J Natl Cancer Inst. 2021;113:1613-1614.
    PubMed    
    
    
    
57. CUI W, Francis PA, Loi S, Hickey M, et al
    Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    J Natl Cancer Inst. 2021;113:1770-1778.
    PubMed     Abstract available
    
    
    
58. KANTOR O, King TA, Shak S, Russell CA, et al
    Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
    J Natl Cancer Inst. 2021;113:1744-1750.
    PubMed     Abstract available
    
    
    
59. BORGES VF
    The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making.
    J Natl Cancer Inst. 2021 Nov 25. pii: 6440063. doi: 10.1093.
    PubMed    
    
    
    
60. LAMBERTINI M, Boni L, Michelotti A, Magnolfi E, et al
    Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients.
    J Natl Cancer Inst. 2021 Nov 25. pii: 6440062. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. NEGOITA S, Ramirez-Pena E
    Prevention of Late Recurrence: An Increasingly Important Target for Breast Cancer Research and Control.
    J Natl Cancer Inst. 2021 Nov 8. pii: 6423213. doi: 10.1093.
    PubMed    
    
    
    
62. PEDERSEN RN, Esen BO, Mellemkjaer L, Christiansen P, et al
    The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis.
    J Natl Cancer Inst. 2021 Nov 8. pii: 6423212. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. GEUZINGE HA, Bakker MF, Heijnsdijk EAM, van Ravesteyn NT, et al
    Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
    J Natl Cancer Inst. 2021;113:1476-1483.
    PubMed     Abstract available
    
    
    
64. KUHL CK, Baltzer P
    You Get What You Pay For: Breast MRI Screening of Women With Dense Breasts Is Cost-effective.
    J Natl Cancer Inst. 2021;113:1439-1441.
    PubMed    
    
    
    
65. NIELSEN TO, Leung SCY, McShane LM, Dowsett M, et al
    Response to Zhang and Yang.
    J Natl Cancer Inst. 2021;113:1597-1598.
    PubMed    
    
    
    October 2021
66. MANDELBLATT JS, Zhou X, Small BJ, Ahn J, et al
    Response to Dekker, Stege, and Versteeg.
    J Natl Cancer Inst. 2021;113:1436-1437.
    PubMed    
    
    
    
67. NICKEL B, Copp T, Brennan M, Farber R, et al
    The Impact of Breast Density Information or Notification on Women's Cognitive, Psychological, and Behavioral Outcomes: A Systematic Review.
    J Natl Cancer Inst. 2021;113:1299-1328.
    PubMed     Abstract available
    
    
    September 2021
68. SPRAGUE BL, Lowry KP, Miglioretti DL, Alsheik N, et al
    Changes in Mammography Use by Women's Characteristics During the First 5 Months of the COVID-19 Pandemic.
    J Natl Cancer Inst. 2021;113:1161-1167.
    PubMed     Abstract available
    
    
    
69. DE JONGE MM, de Kroon CD, Jenner DJ, Oosting J, et al
    Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    J Natl Cancer Inst. 2021;113:1203-1211.
    PubMed     Abstract available
    
    
    
70. JATOI I, Pinsky PF
    Breast Cancer Screening Trials: Endpoints and Overdiagnosis.
    J Natl Cancer Inst. 2021;113:1131-1135.
    PubMed     Abstract available
    
    
    August 2021
71. HERSHMAN DL, Neugut AI, Moseley A, Arnold KB, et al
    Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.
    J Natl Cancer Inst. 2021;113:989-996.
    PubMed     Abstract available
    
    
    
72. YAO S, Cheng TD, Elkhanany A, Yan L, et al
    Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion.
    J Natl Cancer Inst. 2021;113:1036-1043.
    PubMed     Abstract available
    
    
    
73. RUDDY KJ, Schaid DJ, Batzler A, Cecchini RS, et al
    Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.
    J Natl Cancer Inst. 2021;113:1105-1108.
    PubMed     Abstract available
    
    
    July 2021
74. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
    Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2021
75. WANG J, Peng C, Guranich C, Heng YJ, et al
    Early-Life Body Adiposity and the Breast Tumor Transcriptome.
    J Natl Cancer Inst. 2021;113:778-784.
    PubMed     Abstract available
    
    
    May 2021
76. PUNGLIA RS, Partridge AH
    Optimizing Decision Making for Ductal Carcinoma in Situ: Facts Over Fear.
    J Natl Cancer Inst. 2021;113:511-512.
    PubMed    
    
    
    April 2021
77. VAN DEN BROEK JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, et al
    Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    J Natl Cancer Inst. 2021;113:434-442.
    PubMed     Abstract available
    
    
    
78. MAGUIRE S, Perraki E, Tomczyk K, Jones ME, et al
    Common Susceptibility Loci for Male Breast Cancer.
    J Natl Cancer Inst. 2021;113:453-461.
    PubMed     Abstract available
    
    
    
79. MAGBANUA MJM, Hendrix LH, Hyslop T, Barry WT, et al
    Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
    J Natl Cancer Inst. 2021;113:443-452.
    PubMed     Abstract available
    
    
    
80. FRANZOI MA, Eiger D, Ameye L, Ponde N, et al
    Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
    J Natl Cancer Inst. 2021;113:462-470.
    PubMed     Abstract available
    
    
    March 2021
81. O'LEARY B, Cutts RJ, Huang X, Hrebien S, et al
    Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    J Natl Cancer Inst. 2021;113:309-317.
    PubMed     Abstract available
    
    
    
82. KAPOOR PM, Mavaddat N, Choudhury PP, Wilcox AN, et al
    Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.
    J Natl Cancer Inst. 2021;113:329-337.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: